Immorna specializes in the development of RNA-based therapeutics to target genetic disorders and infectious diseases. By utilizing advanced RNA synthesis techniques, the company aims to provide precise and effective treatment options that address unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Many genetic disorders and infectious diseases lack effective treatments due to the difficulty of targeting specific cellular mechanisms with traditional drugs. Developing targeted therapies for these conditions requires innovative approaches that can precisely modulate gene expression and protein production.
Solution
Immorna is developing RNA-based therapeutics designed to address genetic disorders and infectious diseases. The company leverages advanced RNA synthesis techniques to create precise and effective treatment options. Immorna's approach focuses on modulating gene expression at the RNA level, allowing for targeted intervention in disease pathways. By delivering therapeutic RNA molecules directly to cells, Immorna aims to correct genetic defects and combat infectious agents with greater specificity and efficacy than traditional methods. This technology has the potential to create novel treatments for conditions with limited or no existing therapeutic options.
Target Audience
Immorna's primary target audience includes patients suffering from genetic disorders and infectious diseases, as well as pharmaceutical companies seeking innovative therapeutic modalities.
Features
- RNA synthesis platform for creating custom-designed RNA therapeutics
- Targeted delivery mechanisms to ensure RNA reaches specific cells and tissues
- RNA modification techniques to enhance stability and reduce immune response
- In vitro and in vivo testing to validate therapeutic efficacy and safety
- Development of RNA-based vaccines for infectious diseases